T. Rowe Price Associates, Inc. (I. recently announced the acquisition of new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). The institutional investor has increased its shareholding in the Healthcare company by 40.56% to 6.62 million shares with purchase of 1.91 million shares. This fresh investment now brings its stake to 11.08% valued currently at $453.13 million. In addition, Capital Research & Management Co. raised its holdings by 0.21 million to 6.57 million shares. And Capital Research & Management Co. has lifted its position by 1.48% or 89619.0 shares – to 6.13 million shares.
With over 0.26 million Ultragenyx Pharmaceutical Inc. (RARE) shares trading Friday and a closing price of $86.26 on the day, the dollar volume was approximately $22.24 million. The shares have shown a positive weekly performance of 0.26% and its price on 07/10/20 lost nearly -1.92%. Currently, there are 58.00M common shares owned by the public and among those 56.15M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 19 analysts who have offered their price forecasts for RARE have a consensus price objective of $82.11. The analysts have set the share’s price value over the next 12 months at a high of $94.00 and a low of $57.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Ultragenyx Pharmaceutical Inc. stock is 1.80 for the next 12 months. The average price target is -5.2% below its last price level and a downside to the estimated low will see the stock lose -51.33% over that period. But an upside of 8.23% will see the stock hit the forecast high price target while mean target price for the stock is $83.00.
Insiders at the company have transacted a total of 103 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 49 of these insider trades were purchases, accounting for 407,851 shares. Insider sales of the common stock occurred on 54 occasions, with total insider shares sold totaling 123,412 shares.
The top 3 mutual fund holders in Ultragenyx Pharmaceutical Inc. are American Funds Growth Fund of Ame, American Funds New Perspective Fu, and American Funds Fundamental Invest. American Funds Growth Fund of Ame owns 4.9 million shares of the company’s stock, all valued at over $335.18 million. The company bought an additional 0.29 million shares recently to bring their total holdings to about 8.19% of the shares outstanding. American Funds Fundamental Invest now owns shares totaling to 3.78% of the shares outstanding.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) opened at $88.32, up $0.37 from a prior closing price of $87.95. However, the script later closed the day at $86.26, down -1.92%. The company’s stock has a 5-day price change of 0.26% and 64.30% over the past three months. RARE shares are trading 101.97% year to date (YTD), with the 12-month market performance up to 47.00% higher. It has a 12-month low price of $31.99 and touched a high of $91.77 over the same period. Currently, 0.26 million shares have been traded, compared to an average intraday trading volume of 569.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.01%, 19.64%, and 60.23% respectively.
Institutional ownership of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) 58.00M shares outstanding. Mutual fund holders own 27.55%, while other institutional holders and individual stakeholders account for 77.83% and 13.85% respectively.
It has a market capitalization of $5.07B and a beta (3y monthly) value of 2.25. The earnings-per-share (ttm) stands at -$7.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.43% over the week and 5.35% over the month.
Analysts forecast that Ultragenyx Pharmaceutical Inc. (RARE) will achieve an EPS of -$1.55 for the current quarter, -$1.48 for the next quarter and -$5 for 2021. The lowest estimate earnings-per-share for the quarter is -$1.85 while analysts give the company a high EPS estimate of -$0.82. Comparatively, EPS for the current quarter was -$1.72 a year ago. Earnings per share for the fiscal year are expected to decrease by -79.30%, and 22.20% over the next financial year. EPS should grow at an annualized rate of 17.20% over the next five years, compared to -25.90% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 19 brokerage firm advisors rate Ultragenyx Pharmaceutical Inc. (RARE) as a “Strong Buy” at a consensus score of 1.80. Specifically, 14 Wall Street analysts polled rate the stock as a buy, while 4 of the 19 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RARE, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on August 02, 2019, with the firm’s price target at $75. Morgan Stanley coverage for the Ultragenyx Pharmaceutical Inc. (RARE) stock in a research note released on March 27, 2019 offered a Overweight rating with a price target of $83. Raymond James was of a view on February 22, 2019 that the stock is Outperform, while Raymond James gave the stock Mkt Perform rating on January 02, 2019, issuing a price target of. Citigroup on their part issued Neutral rating on November 08, 2018.